Project Grant HT94252510155
Award Date
4/1/25
Completion Date
3/31/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
The Defense Health Agency awarded a $458,516 Project Grant to Mayo Clinic Jacksonville to support research titled "NOVEL THERAPEUTICS TARGETING STRESS GRANULES FOR C9ORF72-MEDIATED ALS." The grant period runs from February 1, 2021 through June 30, 2022.
The grant supports research into novel therapeutics targeting stress granules for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9orf72 gene. This work falls under the Military Medical Research and...
The U.S. Defense Health Agency has awarded a $1,187,875 Project Grant to Mayo Clinic to support the research project "INVESTIGATING MOLECULAR MECHANISMS UNDERLYING THE CILIARY TRAFFICKING OF POLYCYSTINS". This grant, awarded on April 1, 2024 under the Military Medical Research and Development program (CFDA 12.420), will fund research to advance the understanding of the molecular mechanisms involved in the trafficking of polycystins through cellular cilia. The project aims to yield...
Mayo Clinic was awarded a $8,966,819 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from July 1, 2023 to June 30, 2027 to further develop purified exosome products for treating pulmonary damage from toxic exposures, leveraging Mayo Clinic's expertise in exosome applications. Through this funding, Mayo Clinic aims to advance biomedical solutions applicable to both military and civilian...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Defense Health Agency awarded The Trustees of the University of Pennsylvania $750,484 under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The project aims to identify plasma biomarkers in amyotrophic lateral sclerosis (ALS) and related disorders that can classify clinical subtypes and provide prognostic information. Specifically, the University of Pennsylvania will evaluate plasma P-tau181 and neurofilament light...
The Department of Defense's Defense Health Agency awarded a $322,800 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Mayo Clinic in Rochester, Minnesota. The grant, with a performance period from April 1, 2024 to March 31, 2026, supports research on "MYELOPEROXIDASE PROMOTES PERSISTENT FIBROSIS." As a renowned non-profit academic medical center, Mayo Clinic will leverage its expertise in clinical care, biomedical research, and medical...
Mayo Clinic will receive $795,000 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct the project "PHARMACODYNAMIC BIOMARKER-GUIDED METABOLIC COLLAPSE OF IDH-MUTANT GLIOMA" from September 2021 through September 2024. This Project Grant aims to develop medical solutions for the battlefield by investigating pharmacodynamic biomarkers to guide targeted metabolic therapies for the treatment of isocitrate...
The Mayo Clinic was awarded a $1,605,726.00 Cooperative Agreement from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to provide treatment of pulmonary insults from acute and chronic toxic exposures using purified exosome products. The project aims to investigate medical solutions for the battlefield through innovative and impactful research focused on transforming health care for Service Members and the American public. The 3-year project...
The federal Project Grant award of $161,400.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research project titled "AN ATLAS OF THE TUMOR IMMUNE CIRCULOME." This award, with a performance period from June 1, 2024 to May 31, 2025, aims to advance medical knowledge and improve patient care through innovative biomedical research. The Military Medical Research and Development program funds a wide range of...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....